IL6 in Liver cirrhosis

Key issues concerning the case

7513204 PDF 1994. Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice.Template:7513204
2505958 PDF 1989. High interleukin-6 serum levels and increased production by leucocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokines production.Template:2505958
10613740 PDF 2000. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice.Template:10613740
10534116 PDF 1999. Attenuated liver fibrosis and depressed serum albumin levels in carbon tetrachloride-treated IL-6-deficient mice.Template:10534116
8972745 PDF 1996. Anti-interleukin-6 autoantibodies in plasma are associated with an increased frequency of infections and increased mortality of patients with alcoholic cirrhosis.Template:8972745
1397888 PDF 1992. Immunoglobulin A and interleukin 6 form a positive secretory feedback loop: a study of normal subjects and alcoholic cirrhotics.Template:1397888

Cirrhosis makes IL6

26855498 PDF 2016. Carbohydrate Deficient Transferrin and Interleukin-6 as Predictors of Fibrosis in Alcohol Cirrhosis.Template:26855498
26807383 PDF 2015. IL-6 Plays a Crucial Role in HBV Infection.Template:26807383
26573228 PDF 2015. LPS-induced TNF-alpha factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.Template:26573228
26448742 PDF 2015. Proinflammatory Cytokines (IL-1alpha, IL-6) and Hepatocyte Growth Factor in Patients with Alcoholic Liver Cirrhosis.Template:26448742
26090463 PDF 2015. Liver Failure Impairs the Intrahepatic Elimination of Interleukin-6, Tumor Necrosis Factor-Alpha, Hepatocyte Growth Factor, and Transforming Growth Factor-Beta.Template:26090463
26039496 PDF 2015. Detecting minimal hepatic encephalopathy in an endemic country for hepatitis B: the role of psychometrics and serum IL-6.Template:26039496
25899133 PDF 2017. IL-6 significantly correlates with p-STAT3 expression and presents high variceal bleeding with mortality in cirrhotic patients: A cross-sectional study.Template:25899133
25870985 PDF 2015. Association of HIV, hepatitis C virus and liver fibrosis severity with interleukin-6 and C-reactive protein levels.Template:25870985
25421508 PDF 2014. Stratification of risk of death in severe acute alcoholic hepatitis using a panel of adipokines and cytokines.Template:25421508
25214799 PDF 2014. Interleukins in chronic liver disease: lessons learned from experimental mouse models.Template:25214799
24849676 PDF 2014. Purinergic signaling via P2Y receptors up-mediates IL-6 production by liver macrophages/Kupffer cells.Template:24849676
23928410 PDF 2013. Uncovering the molecular events associated with increased intestinal permeability in liver cirrhosis: the pivotal role of enterocyte tight junctions and future perspectives.Template:23928410
23813132 PDF 2013. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.Template:23813132
23515243 PDF 2012. Tumor necrosis factor-alpha and interleukin-6 in cirrhotic patients with spontaneous bacterial peritonitis.Template:23515243
23150092 PDF 2013. Hepatitis C virus promotes T-helper (Th)17 responses through thymic stromal lymphopoietin production by infected hepatocytes.Template:23150092
23144154 PDF 2012. Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73.Template:23144154
22851861 PDF 2012. Lentiviral vector-mediated down-regulation of IL-17A receptor in hepatic stellate cells results in decreased secretion of IL-6.Template:22851861
22687286 PDF 2012. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice.Template:22687286
22507133 PDF 2012. Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate.Template:22507133
21622209 PDF 2011. JAK-STAT signaling in hepatic fibrosis.Template:21622209
19950277 PDF 2009. Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia.Template:19950277
19855130 PDF 2009. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha.Template:19855130
19652645 PDF 2009. Cholestasis downregulate hepcidin expression through inhibiting IL-6-induced phosphorylation of signal transducer and activator of transcription 3 signaling.Template:19652645
19604266 PDF 2009. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis.Template:19604266
19438606 PDF 2009. An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease.Template:19438606
19032584 PDF 2009. Molecular mechanisms of alcoholic fatty liver.Template:19032584
17962206 PDF 2008. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma.Template:17962206
16688802 PDF 2006. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.Template:16688802
16266225 PDF 2005. IL-6 and extracellular matrix remodeling.Template:16266225
15860640 PDF 2005. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells.Template:15860640
15763341 PDF 2005. Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression.Template:15763341
12547716 PDF 2003. Expression and DNA-binding activity of signal transducer and activator of transcription 3 in alcoholic cirrhosis compared to normal liver and primary biliary cirrhosis in humans.Template:12547716
12077104 PDF 2002. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6.Template:12077104
11337499 PDF 2001. JunD regulates transcription of the tissue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated hepatic stellate cells.Template:11337499
10793074 PDF 2000. The development and compensation of biliary cirrhosis in interleukin-6-deficient mice.Template:10793074
9524291 PDF 1998. Flow cytometric analysis of IL-6 receptors on peripheral lymphocytes in patients with primary biliary cirrhosis.Template:9524291
9524290 PDF 1998. Analysis of serum cytokine levels in primary biliary cirrhosis patients and healthy adults.Template:9524290
8586322 PDF 1995. Increased concentrations of tumor necrosis factor and interleukin-6 contribute to the hemostatic abnormalities in advanced liver disease.Template:8586322
8137551 PDF 1994. IL-6 induces hepatic inflammation and collagen synthesis in vivo.Template:8137551
8137550 PDF 1994. Induction of autoimmune disease by graft-versus-host reaction across MHC class II difference: modification of the lesions in IL-6 transgenic mice.Template:8137550
1597519 PDF 1992. Localisation of intrahepatic interleukin 6 in patients with acute and chronic liver disease.Template:1597519
2044224 PDF 1991. Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis.Template:2044224
23262249 PDF 2013. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.Template:23262249
23084463 PDF 2013. Correlation between interleukin-6 and ammonia in patients with overt hepatic encephalopathy due to cirrhosis.Template:23084463
22883217 PDF 2012. Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy.Template:22883217
22710653 PDF 2012. Laparoscopic and open splenectomy for splenomegaly secondary to liver cirrhosis: an evaluation of immunity.Template:22710653
22646055 PDF 2012. Relationship between interleukin-6 and ammonia in patients with minimal hepatic encephalopathy due to liver cirrhosis.Template:22646055
22634708 PDF 2012. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases.Template:22634708
22510812 PDF 2012. TH-1 and TH-2 cytokines in stable chronic alcoholics.Template:22510812
22367091 PDF 2012. Cytokines in alcoholic liver disease.Template:22367091
22230324 PDF 2012. Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naive hepatitis B infection patients.Template:22230324
21830421 PDF 2011. The relation between pathogenesis of liver cirrhosis, hepatic encephalopathy and serum cytokine levels: what is the role of tumor necrosis factor alpha?Template:21830421
21435128 PDF 2011. Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis.Template:21435128
21421621 PDF 2011. Serum interleukin 6 levels and cirrhosis-associated pulmonary hypertension.Template:21421621
21356197 PDF 2011. Involvement of STAT3-regulated hepatic soluble factors in attenuation of stellate cell activity and liver fibrogenesis in mice.Template:21356197
21228704 PDF 2011. Portal levels of latent transforming growth factor-beta are related to liver function in patients with liver cirrhosis.Template:21228704
20832949 PDF 2011. Endotoxaemia in the pathogenesis of cytopenias in liver cirrhosis. Could oral antibiotics raise blood counts?Template:20832949
20731703 PDF 2011. Peritoneal macrophage priming in cirrhosis is related to ERK phosphorylation and IL-6 secretion.Template:20731703
20637651 PDF 2011. Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis.Template:20637651
20456041 PDF 2010. Admission levels and early changes in serum interleukin-10 are predictive of poor outcome in acute liver failure and decompensated cirrhosis.Template:20456041
20193684 PDF 2010. Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis.Template:20193684
19760951 PDF 2009. Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma.Template:19760951
18562979 PDF 2009. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy.Template:18562979
18455423 PDF 2008. IL-6 Promotes compensatory liver regeneration in cirrhotic rat after partial hepatectomy.Template:18455423
17591083 PDF 2007. Interleukin-6 sustains hepatic regeneration in cirrhotic rat.Template:17591083
17537833 PDF 2007. Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2.Template:17537833
17442294 PDF 2007. Vitamin B12 and hepatic enzyme serum levels correlate with interleukin-6 in alcohol-dependent individuals without liver disease.Template:17442294
16698422 PDF 2006. Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection.Template:16698422
16629651 PDF 2006. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways.Template:16629651
16617007 PDF 2006. Chronic bile duct obstruction induces changes in plasma and hepatic levels of cytokines and nitric oxide in the rat.Template:16617007
16496306 PDF 2006. Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair.Template:16496306
15532800 PDF 2004. Interleukin-6 augments hepatocyte growth factor-induced liver regeneration; involvement of STAT3 activation.Template:15532800
15482340 PDF 2004. Implication of inflammation-related cytokines in the natural history of liver cirrhosis.Template:15482340
12830005 PDF 2003. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases.Template:12830005
10755697 PDF 2000. Does IL-6 regulate liver fibrosis/cirrhosis directly and indirectly?Template:10755697
11059648 PDF 2000. Serum levels of cytokines in alcoholic liver cirrhosis and pancreatitis.Template:11059648
10928624 PDF 2000. Serum interleukin-6 and interferon-gamma levels in patients with hepatitis B-associated chronic liver disease.Template:10928624
10520881 PDF 1999. Soluble interleukin-6 receptor levels in liver cirrhosis.Template:10520881
10377517 PDF 1999. IL-6 and gp130 signalling: its role in chronic disease.Template:10377517
10102225 PDF 1999. Thrombopoietic cytokines and reversal of thrombocytopenia after liver transplantation.Template:10102225
9934750 PDF 1999. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis.Template:9934750
9858790 PDF 1998. Changes in serum thrombopoietin levels after splenectomy.Template:9858790
9166969 PDF 1997. Increased serum concentration of IgA2 subclass and IgA2/IgA1 ratio: specific markers of chronic alcoholic abuse?Template:9166969
9155709 PDF 1997. Cytokines and the hepatic acute phase response.Template:9155709
8734349 PDF 1996. Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation.Template:8734349
8531597 PDF 1995. High interleukin-6 production within the peritoneal cavity in decompensated cirrhosis and malignancy-related ascites.Template:8531597
7540697 PDF 1995. Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS. Correlation with serum interleukin-6 levels and organ dysfunction.Template:7540697
7532385 PDF 1995. Antioxidative roles of metallothionein and manganese superoxide dismutase induced by tumor necrosis factor-alpha and interleukin-6.Template:7532385
7930484 PDF 1994. Interleukin-6: an early marker of bacterial infection in decompensated cirrhosis.Template:7930484
7528963 PDF 1994. Cytokines and the liver in health and disease. Effects on liver metabolism and fibrogenesis.Template:7528963
8281862 PDF 1994. High interleukin-6 concentrations in hepatic ascites.Template:8281862
7511536 PDF 1993. Spontaneous bacterial peritonitis is associated with high levels of interleukin-6 and its secondary mediators in ascitic fluid.Template:7511536
7980730 PDF 1993. High levels of tumor necrosis factor-alpha and interleukin-6 in the ascitic fluid of cirrhotic patients with spontaneous bacterial peritonitis.Template:7980730
8482461 PDF 1993. Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients.Template:8482461
8352843 PDF 1993. Tumour necrosis factor, interleukin-1 and interleukin-6 in alcoholic cirrhosis.Template:8352843
8440420 PDF 1993. Interleukin 6 production by peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection and primary biliary cirrhosis.Template:8440420
1612333 PDF 1992. Serum levels of cytokines in chronic liver diseases.Template:1612333
1447505 PDF 1992. Interleukin-6 production by peripheral blood monocytes in patients with chronic liver disease and acute viral hepatitis.Template:1447505
1736391 PDF 1992. Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery.Template:1736391
1962626 PDF 1991. Serum interleukin 6 levels in patients with chronic hepatitis B.Template:1962626
1753710 PDF 1991. Characterization of fat-storing cell lines derived from normal and CCl4-cirrhotic livers. Differences in the production of interleukin-6.Template:1753710
1995437 PDF 1991. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients.Template:1995437
1772964 PDF 1991. Genes for interleukin-1, interleukin-6, and tumor necrosis factor are expressed at markedly reduced levels in the livers of patients with severe liver disease.Template:1772964
2184115 PDF 1990. Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis.Template:2184115

further aspects

28167322 PDF 2017. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.Template:28167322
28061755 PDF 2017. High serum resistin associates with intrahepatic inflammation and necrosis: an index of disease severity for patients with chronic HBV infection.Template:28061755
27277679 PDF 2016. DJ-1 deficiency attenuates expansion of liver progenitor cells through modulating the inflammatory and fibrogenic niches.Template:27277679
27226903 PDF 2016. Mechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation.Template:27226903
27035642 PDF 2016. Inhibition of the translocation and extracellular release of high-mobility group box 1 alleviates liver damage in fibrotic mice in response to D-galactosamine/lipopolysaccharide challenge.Template:27035642
26728971 PDF 2016. A deleterious role for Th9/IL-9 in hepatic fibrogenesis.Template:26728971
26718412 PDF 2016. Coenzyme Q10 prevents hepatic fibrosis, inflammation, and oxidative stress in a male rat model of poor maternal nutrition and accelerated postnatal growth.Template:26718412
26155043 PDF 2015. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.Template:26155043
25886887 PDF 2015. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.Template:25886887
25747515 PDF 2016. Synergic chemoprevention with dietary carbohydrate restriction and supplementation of AMPK-activating phytochemicals: the role of SIRT1.Template:25747515
25663772 PDF 2015. Interleukin-22 ameliorates liver fibrogenesis by attenuating hepatic stellate cell activation and downregulating the levels of inflammatory cytokines.Template:25663772
25171482 PDF 2014. Oxymatrine improves intestinal epithelial barrier function involving NF-kappaB-mediated signaling pathway in CCl4-induced cirrhotic rats.Template:25171482
24841946 PDF 2014. Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells.Template:24841946
24686514 PDF 2014. Signal transduction of platelet-induced liver regeneration and decrease of liver fibrosis.Template:24686514
24616573 PDF 2014. Impaired balance of T helper 17/T regulatory cells in carbon tetrachloride-induced liver fibrosis in mice.Template:24616573
24616207 PDF 2014. Macrophages and fibrosis in adipose tissue are linked to liver damage and metabolic risk in obese children.Template:24616207
24383550 PDF 2014. The effect of antifibrotic drug halofugine on Th17 cells in concanavalin A-induced liver fibrosis.Template:24383550
24260182 PDF 2013. The heme oxygenase system rescues hepatic deterioration in the condition of obesity co-morbid with type-2 diabetes.Template:24260182
24225281 PDF 2014. Lipopolysaccharide binding protein in cirrhotic patients with severe sepsis.Template:24225281
23840855 PDF 2013. Schistosomajaponicum Eggs Induce a Proinflammatory, Anti-Fibrogenic Phenotype in Hepatic Stellate Cells.Template:23840855
23531302 PDF 2013. Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice.Template:23531302
23299899 PDF 2013. Reticulon 4B (Nogo-B) facilitates hepatocyte proliferation and liver regeneration in mice.Template:23299899
22916250 PDF 2012. Beta-adrenergic receptor 1 selective antagonism inhibits norepinephrine-mediated TNF-alpha downregulation in experimental liver cirrhosis.Template:22916250
22890552 PDF 2012. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture.Template:22890552
22120983 PDF 2012. Toll-like receptor 4-dependent Kupffer cell activation and liver injury in a novel mouse model of parenteral nutrition and intestinal injury.Template:22120983
22117531 PDF 2012. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease.Template:22117531
21562239 PDF 2011. Suppression of amphiregulin/epidermal growth factor receptor signals contributes to the protective effects of quercetin in cirrhotic rats.Template:21562239
21314960 PDF 2011. Induction of heme oxygenase-1 protects against nutritional fibrosing steatohepatitis in mice.Template:21314960
21284667 PDF 2011. Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines.Template:21284667
19676135 PDF 2009. Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6.Template:19676135
19161105 PDF 2008. Changes in adrenal steroidogenesis in spontaneous bacterial peritonitis and sterile ascites.Template:19161105
19065675 PDF 2009. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis.Template:19065675
18794850 PDF 2008. Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice.Template:18794850
18571789 PDF 2008. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis.Template:18571789
18202114 PDF 2008. IL-6 downregulates transcription of NTPDase2 via specific promoter elements.Template:18202114
16844679 PDF 2006. Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model.Template:16844679
15194060 PDF 2004. Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats.Template:15194060
12594232 PDF 2003. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis.Template:12594232
28251449 PDF 2017. A20 Attenuates Liver Fibrosis in NAFLD and Inhibits Inflammation Responses.Template:28251449
26957302 PDF 2017. Associations Between Hepatic Functions and Plasma Amyloid-Beta Levels-Implications for the Capacity of Liver in Peripheral Amyloid-Beta Clearance.Template:26957302
26278387 PDF 2017. Review: Precision Cut Liver Slices for the Evaluation of Fatty Liver and Fibrosis.Template:26278387
25908229 PDF 2015. Neurologic Manifestations of Chronic Liver Disease and Liver Cirrhosis.Template:25908229
25416630 PDF 2015. Depletion of Foxp3+ Regulatory T Cells Promotes Profibrogenic Milieu of Cholestasis-Induced Liver Injury.Template:25416630
24620819 PDF 2015. Albumin infusion improves renal blood flow autoregulation in patients with acute decompensation of cirrhosis and acute kidney injury.Template:24620819
24239319 PDF 2014. Protective effects of L-carnitine, N-acetylcysteine and genistein in an experimental model of liver fibrosis.Template:24239319
23998651 PDF 2014. Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.Template:23998651
23948302 PDF 2013. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.Template:23948302
23855303 PDF 2013. Interaction of hepatic stellate cells with diverse types of immune cells: foe or friend?Template:23855303
23871639 PDF 2013. The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies.Template:23871639
23842754 PDF 2013. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation.Template:23842754
23728792 PDF 2013. Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death.Template:23728792
23511062 PDF 2013. Effect of endotoxin on heart rate dynamics in rats with cirrhosis.Template:23511062
23425082 PDF 2013. Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy.Template:23425082
23350952 PDF 2013. Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: potential biomarkers for a more favorable prognosis?Template:23350952
22683883 PDF 2012. Protective effects of curcumin against hepatic fibrosis induced by carbon tetrachloride: modulation of high-mobility group box 1, Toll-like receptor 4 and 2 expression.Template:22683883
22185916 PDF 2012. Magnesium chenoursodeoxycholic acid ameliorates carbon tetrachloride-induced liver fibrosis in rats.Template:22185916
22098272 PDF 2012. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia.Template:22098272
22068968 PDF 2012. Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice.Template:22068968
21822824 PDF 2011. Chronic inflammation and hepatocellular carcinoma.Template:21822824
21742296 PDF 2011. Liver fibrogenesis and metabolic factors.Template:21742296
21275501 PDF 2011. Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis.Template:21275501
20969493 PDF 2011. Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice.Template:20969493
20931291 PDF 2011. A natural process of cirrhosis resolution and deceleration of liver regeneration after thioacetamide withdrawal in a rat model.Template:20931291
20399524 PDF 2010. Harmful effect of adipose tissue on liver lesions in patients with alcoholic liver disease.Template:20399524
19857658 PDF 2009. Intestine as source of cytokines and growth factors.Template:19857658
19642894 PDF 2009. Interleukin-6 trans-signaling regulates glycogen consumption after D-galactosamine-induced liver damage.Template:19642894
19502117 PDF 2010. Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage.Template:19502117
19413671 PDF 2009. Inhibition of hepatic tumour necrosis factor-alpha attenuates the anandamide-induced vasoconstrictive response in cirrhotic rat livers.Template:19413671
19220679 PDF 2009. Pentoxifylline prevents pig serum-induced rat liver fibrosis by inhibiting interleukin-6 production.Template:19220679
19118554 PDF 2009. B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis.Template:19118554
18627003 PDF 2008. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease.Template:18627003
18600481 PDF 2009. Inflammatory pathways in liver homeostasis and liver injury.Template:18600481
18395094 PDF 2008. Nuclear factor-eythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury.Template:18395094
17998145 PDF 2008. Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin.Template:17998145
17906854 PDF 2008. Hyperreninemic hypoaldosteronism syndrome, plasma concentrations of interleukin-6 and outcome in critically ill patients with liver cirrhosis.Template:17906854
17512085 PDF 2007. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences.Template:17512085
17222322 PDF 2007. An inverse relationship between markers of fibrogenesis and collagen degradation in patients with or without alcoholic liver disease.Template:17222322
16941689 PDF 2006. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation.Template:16941689
15990591 PDF 2005. Nonalcoholic fatty liver disease and the metabolic syndrome.Template:15990591
15664244 PDF 2005. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis.Template:15664244
15074396 PDF 2004. Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease.Template:15074396
12640528 PDF 2003. Interleukin 6 concentration in ascitic fluid of cirrhotic patients: relationship with previous episodes of spontaneous bacterial peritonitis.Template:12640528
12189115 PDF 2002. Small bowel bacterial overgrowth and endotoxemia in cirrhosis.Template:12189115
12115021 PDF 2002. Furosemide: progress in understanding its diuretic, anti-inflammatory, and bronchodilating mechanism of action, and use in the treatment of respiratory tract diseases.Template:12115021
10755691 PDF 2000. Induction of hepatic stellate cell proliferation by LPS-stimulated peripheral blood mononuclear cells from patients with liver cirrhosis.Template:10755691
10535885 PDF 1999. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential.Template:10535885
10493891 PDF 1999. Fibrosin: A novel lymphokine in alcohol-induced fibrosis.Template:10493891
10395040 PDF 1999. Inhibition of concanavalin A-induced acute T cell dependent hepatic damage in mice by hypothyroidism.Template:10395040
9888410 PDF 1999. Treatment with glutathione precursor decreases cytokine activity.Template:9888410
9622456 PDF 1998. Altered T-lymphocyte responsiveness to polyclonal cell activators is responsible for liver cell necrosis in alcohol-fed rats.Template:9622456
9581682 PDF 1998. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor.Template:9581682
7533191 PDF 1995. Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo.Template:7533191
8589343 PDF 1995. Roles of oxidative stress in activation of Kupffer and Ito cells in liver fibrogenesis.Template:8589343
1639344 PDF 1992. Immunomodulatory effects of ursodeoxycholic acid on immune responses.Template:1639344